Abstract:Topic: 16. Myeloproliferative neoplasms - Clinical Background: Polycythemia vera (PV) is one of the myeloproliferative neoplasms (MPNs) characterized by the overproduction of morphologically and functionally normal blood cells. Whereas, the relationship between hematologic neoplasms related genetic mutations and clinical characteristics is still under investigation. Aims: This study aimed to explore the impact of JAK2 gene mutational status and allele burden, WT1 gene expression level and hematologic neoplasms related genetic mutations on clinical characteristics and prognosis of polycythemia vera (PV). Methods: We retrospectively reviewed the clinical parameters and hematologic information of 275 patients in China from January 2015 to August 2022 (ChiCTR2200061208), and analyzed the relationship between JAK2 gene mutation, WT1 gene expression level, hematologic neoplasms related genetic mutations and clinical characteristics of polycythemia vera. Results: Patients with JAK2V617F mutation (A) had the oldest onset age(vs B, P=0.036; vs C, P<0.001), patients with JAK2 exon12 mutation (B) had the highest hemoglobin values(vs A, P=0.031; vs C, P=0.010), and JAK2 unmutated patients (C) had the lowest leukocyte counts(vs A, P<0.001; vs B, P=0.024) and lactate dehydrogenase level(vs A, P<0.001; vs B, P<0.001) (FigureA). JAK2 V617F allele burden was positively correlated with the age of onset(P=0.001, r=0.251), leukocyte counts(P<0.001, r=0.466) and lactate dehydrogenase values(P<0.001, r=0.320) (FigureB). Patients with PV had higher expression level of WT1 than patients with non-hematologic malignancies(P<0.001) (FigureC), and the expression level of WT1 was positively correlated with lactate dehydrogenase value(P=0.011, r=0.460), JAK2V617F allele burden(P=0.004, r=0.528) and fibrosis grade of bone marrow(P=0.044, r=0.390)(FigureD). JAK2 mutated PV patients was more likely to have genetic mutations than JAK2 unmutated patients(P=0.002)(FigureE, F, G). Patients with no less than 3 genetic mutations(P=0.028) and patients with TET2 gene mutation(P=0.001) had higher frequency of splenomegaly (FigureH). Summary/Conclusion: PV patients with different JAK2 gene mutational status had various clinical characteristics. JAK2 V617F allele burden was positively correlated with the age of onset, leukocyte counts and lactate dehydrogenase values. WT1 gene is overexpressed in PV, and the expression level of WT1 was positively correlated with JAK2V617F allele burden. JAK2 mutated PV patients was more likely to have genetic mutations than JAK2 unmutated patients. Patients with no less than 3 genetic mutations and patients with TET2 gene mutation had higher frequency of splenomegaly. This research was funded by Key R&D Program of Zhejiang, No. 2022C03137; Public Technology Application Research Program of Zhejiang, China, No. LGF21H080003; Zhejiang Medical Association Clinical Medical Research special fund project, No. 2022ZYC-D09; Key Project of Jinhua Science and Technology Plan, China, No. 2020-3-011. *Correspondence to: Prof Jian Huang; Prof Jie JinKeywords: Mutation, WT1, Polycythemia vera, Clinical data

Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort

Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis

Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs

Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

[Clinical and Genetic Characteristics of Young Patients with Myeloproliferative Neoplasms].

Features and allele frequency of JAK2 Exon 12-mutated polycythemia vera in comparison with JAK2 V617F-mutated disease

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

PB2217: REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS

Effective Management of Polycythemia Vera with Ropeginterferon Alfa-2b Treatment

Polycythemia vera: past, present and future

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications

Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms

A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan

Age and long-term outcomes of patients with venous thromboembolism: From the COMMAND VTE Registry

[Overall survival and prognosis of patients with polycythemia vera: an analysis based on 906 patients from a single center].

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study

Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China